Recent research highlights advancements in knee osteoarthritis pain management, including specialized injections and the role of medications addressing related health conditions.

Understanding Knee Osteoarthritis Pain

Knee osteoarthritis (OA) is a common condition characterized by the breakdown of cartilage in the knee joint, leading to pain, stiffness, and reduced mobility [1]. It is a degenerative disease that can significantly impact a person's quality of life. Treatment for knee OA aims to relieve pain, improve joint function, and, in some cases, slow disease progression [1]. Recent studies offer new insights into various treatment approaches, particularly for patients with co-occurring health conditions.

Intra-Articular Injections for Targeted Relief

Injections directly into the knee joint are a common strategy for managing OA pain. Two types frequently used are corticosteroids and hyaluronic acid.

Corticosteroids: A newer extended-release form of triamcinolone acetonide (TA-ER) has shown promise for managing knee OA pain [1]. This treatment is particularly relevant for individuals who also have type 2 diabetes. A study found that participants with knee OA and type 2 diabetes who received TA-ER experienced smaller increases and fewer spikes in blood glucose levels compared to those receiving a standard form of the steroid (triamcinolone acetonide crystalline suspension, TAcs), especially in the first three days after the injection [1]. No serious side effects were reported for either TA-ER or TAcs in this study [1].
Hyaluronic Acid (HA): HA injections are widely used in the management of knee OA [2]. However, the effectiveness of HA can vary significantly among patients [2]. Recent research suggests that underlying cardiometabolic conditions, such as type 2 diabetes, high blood pressure (hypertension), or high cholesterol (hyperlipidemia), may influence how well patients respond to HA injections [2]. This highlights the importance of considering a patient's overall health when developing an osteoarthritis treatment plan.

Addressing Comorbidities: The Role of GLP-1 Receptor Agonists

Obesity and type 2 diabetes are common risk factors for developing osteoarthritis and can be associated with worse outcomes following joint replacement surgery [4]. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications primarily known for improving blood sugar control and promoting weight loss [4]. Emerging research explores their potential benefits for osteoarthritis patients, especially those with these comorbidities.

Studies are investigating GLP-1RAs, such as semaglutide, as a strategy to optimize patients before total knee replacement surgery (TKA) [3]. The goal is to improve weight management, which is associated with better outcomes and fewer complications after surgery [3]. A systematic review and meta-analysis found that GLP-1RA treatment was associated with improved 90-day outcomes, including a lower rate of surgical complications, following total hip and knee arthroplasty [4]. Furthermore, research is exploring whether GLP-1RAs might impact the risk of developing osteoarthritis in individuals with type 2 diabetes [5].

Oral Medications: NSAIDs and Important Considerations

Nonsteroidal anti-inflammatory drugs (NSAIDs) are frequently used to manage pain and inflammation associated with osteoarthritis [6]. While effective for many, it is important to be aware of potential side effects. One retrospective study, which focused on migraine patients, identified a possible association between NSAID use and an increased risk of femoral osteonecrosis (a condition where bone tissue dies due to lack of blood supply) [6]. This underscores the importance of discussing all medications and potential risks with your healthcare provider to ensure safe and appropriate use.

When Surgery is Considered: Total Knee Arthroplasty

For severe knee osteoarthritis that does not respond sufficiently to other treatments, total knee arthroplasty (TKA), or total knee replacement surgery, may be recommended [3]. As mentioned, optimizing a patient's health before surgery, particularly managing obesity and diabetes, can significantly improve surgical outcomes and reduce complications [3, 4]. Medications like GLP-1RAs are being studied for their role in this preoperative optimization strategy [3, 4].

Conclusion

Managing knee osteoarthritis pain often involves a multi-faceted approach tailored to the individual's specific needs and overall health profile. Recent research continues to refine existing treatments and explore new strategies, especially for patients with co-occurring conditions like diabetes and obesity. Always consult with your doctor to determine the most appropriate and personalized treatment plan for your specific needs, ensuring all potential benefits and risks are thoroughly discussed.

Sources

[1] Plain Language Summary of a Phase 2 Study of Triamcinolone Acetonide Extended-Release for Pain Relief in People With Knee Osteoarthritis and Type 2 Diabetes. (Therapeutic advances in musculoskeletal disease, 2026) https://pubmed.ncbi.nlm.nih.gov/41978715/

[2] Cardiometabolic disease and risk of total knee arthroplasty among patients with knee osteoarthritis receiving intra-articular hyaluronic acid: a real-world cohort study. (Therapeutic advances in musculoskeletal disease, 2026) https://pubmed.ncbi.nlm.nih.gov/42482885/

[3] Protocol for Novel Perioperative Optimization of Obese Osteoarthritic Patients pending Total Knee Replacement with glucagon-like peptide-1 receptor agonist (NPO-OOPS-TKR) : a pilot randomized controlled trial. (Bone & joint open, 2026) https://pubmed.ncbi.nlm.nih.gov/42402343/

[4] Glucagon-like peptide-1 receptor agonists are associated with improved 90-day outcomes after total hip and knee arthroplasty : a systematic review and meta-analysis. (The bone & joint journal, 2026) https://pubmed.ncbi.nlm.nih.gov/42538001/

[5] The effect of GLP-1 receptor agonists on osteoarthritis risk in individuals with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized controlled trials. (Acta diabetologica, 2026) https://pubmed.ncbi.nlm.nih.gov/42101662/

[6] Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Use Is Associated With an Increased Risk of Femoral Osteonecrosis in Migraine Patients: A Retrospective, TriNetX Database-Based Study. (Cureus, 2025) https://pubmed.ncbi.nlm.nih.gov/41293358/

This article summarises published research for a general audience. It is not medical advice — talk to a qualified clinician about your own situation. Need help finding one? Browse doctors.

Managing Knee Osteoarthritis Pain: Emerging Treatment Insights